Consistent with
prior terms of clearance, FDA is reminded that it will submit an
ICR revision if the Medication Guide program is modified in such a
way that results in new or different information collection
requirements. Any such ICR revisions must be submitted prior to the
modifications taking effect.
Inventory as of this Action
Requested
Previously Approved
01/31/2016
36 Months From Approved
01/31/2013
296,719,031
0
296,719,030
16,907,114
0
16,907,110
0
0
0
FDA regulations require the
distribution of patient labeling, called Medication Guides, for
certain prescription human drugs and biological products used
primarily on an outpatient basis that pose a serious and
significant public health concern requiring distribution of
FDA-approved patient medication information. These Medication
Guides inform patients about the most important information they
should know about these products in order to use them safely and
effectively.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.